High Dose Candesartan Versus Quinapril for Restenosis Prophylaxis After Stent Angioplasty
Not Applicable
Completed
- Conditions
- Arterial Occlusive Diseases
- Registration Number
- NCT00154050
- Lead Sponsor
- Technische Universität Dresden
- Brief Summary
The study is designed to test the hypothesis that high dose candesartan treatment compared to quinapril is able to reduce intima hyperproliferation and the restenosis rate after stent angioplasty in peripheral occlusive artery disease.
- Detailed Description
Patients are randomly assigned to treatment with either candesartan 32 mg/d or Quinapril 20 mg/d before the angioplasty. Walking distance, intima media thickness and crurobrachial pressure ratios are compared after 6 weeks, 3 months and 6 months. After 6 months an angiographic control is performed.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
- male and female
- peripheral occlusive arterial disease Stad IIb Fontaine classification
Exclusion Criteria
- patients with lesions not available for PTA
- renal insufficiency
- patients on calcium-antagonists
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Restenosis/reintervention after 6 months
- Secondary Outcome Measures
Name Time Method crurobrachial pressure ratios pain-free walking distance
Trial Locations
- Locations (1)
Chemnitz Hospital, Dept. of Internal Medicine I
🇩🇪Chemnitz, Germany